Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Bauman

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Pharmacotherapy|January 1, 1989
Results of the cast ... what did we catch?J L Bauman
Pharmacotherapy|December 17, 1998
Amiodarone: the re-emergence of a unique antiarrhythmic drug. IntroductionJ L Bauman
Pharmacotherapy|March 1, 1997
Class III antiarrhythmic agents: the next waveJ L Bauman
Clinical Pharmacy|July 1, 1983
Understanding and treating supraventricular arrhythmiasJ L Bauman
Clinical Pharmacy|July 1, 1986
Current concepts in clinical therapeutics: acute myocardial infarctionF P Zeller, J L Bauman
Pharmacotherapy|November 1, 1995
QT interval prolongation and torsades de pointes due to erythromycin lactobionateK C Oberg, J L Bauman
Drug Intelligence & Clinical Pharmacy|April 1, 1986
Mexiletine: a new type I antiarrhythmic agentB J Schrader, J L Bauman
Pharmacoeconomics|May 8, 1995
Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias. Focus on atrial fibrillation and flutterB G Phillips, J L Bauman
The New England Journal of Medicine|January 13, 1977
Intravenous phenytoinJ L Bauman, J K Siepler
American Journal of Hospital Pharmacy|January 1, 1978
Phenytoin crystallization in intravenous fluidsJ L Bauman, J K Siepler
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Pharmacotherapy|January 1, 1989
Results of the cast ... what did we catch?J L Bauman
Pharmacotherapy|December 17, 1998
Amiodarone: the re-emergence of a unique antiarrhythmic drug. IntroductionJ L Bauman
Pharmacotherapy|March 1, 1997
Class III antiarrhythmic agents: the next waveJ L Bauman
Clinical Pharmacy|July 1, 1983
Understanding and treating supraventricular arrhythmiasJ L Bauman
Clinical Pharmacy|July 1, 1986
Current concepts in clinical therapeutics: acute myocardial infarctionF P Zeller, J L Bauman
Pharmacotherapy|November 1, 1995
QT interval prolongation and torsades de pointes due to erythromycin lactobionateK C Oberg, J L Bauman
Drug Intelligence & Clinical Pharmacy|April 1, 1986
Mexiletine: a new type I antiarrhythmic agentB J Schrader, J L Bauman
Pharmacoeconomics|May 8, 1995
Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias. Focus on atrial fibrillation and flutterB G Phillips, J L Bauman
The New England Journal of Medicine|January 13, 1977
Intravenous phenytoinJ L Bauman, J K Siepler
American Journal of Hospital Pharmacy|January 1, 1978
Phenytoin crystallization in intravenous fluidsJ L Bauman, J K Siepler
Pageof 8